Group B Streptococcus or Streptococcus agalactiae is an encapsulated Gram-positive coccus capable of producing a range of diseases in humans of all ages.
In the neonate, the bacterium can cause severe life threatening sepsis, meningitis and pneumonia (early-onset, EOGBS and late-onset LOGBS disease)
due to ascending spread of GBS from the birth canal of colonized females (~18-30% colonized of total) who are typically asymptomatic. GBS may also contribute to
stillbirth, pre-mature birth, neonatal encephalopathy and long-term neurological outcomes in meningitis survivors.
It can cause perinatal clinical syndromes in the mother during such as maternal sepsis and chorioamnionitis.
Globally, GBS was estimated to have caused 394,000 cases of invasive neonatal disease resulting in 91,900 deaths (95% CI 44,800-187,800) (Goncalves BP et al 2022).
A prophylactic Group B Streptococcus vaccine could prevent invasive disease in a number of target populations both in Western developed countries and the developing world e.g., GAVI-assisted countries.
Several approaches are ongoing in both preclinical and clinical development with the most advanced being the Pfizer, GBS6 vaccine [PF-06760805],
a hexavalent polysaccharide conjugated approach which recently reported positive data from an ongoing Phase 2 study. Danish-based Minervax are also developing an adjuvanted
protein-based GBS vaccine (GBS-NN, GBS-NN2) for maternal (Phase 2) and adult indications (Phase 1).
Other potential approaches are being pursued by Nanjing Agricultural University, China, Inventprise (GBS-06) (now in Phase 1) and the US-biotech, Omniose. AstraZeneca now have an interest in the Omniose program.
This MarketVIEW product is a comprehensive Executive Presentation (>300 slides, .pdf) and interactive MS-Excel forecast model (120 worksheets, .xls)
which investigate the scenario-based uptake and commercial potential of Group B Streptococcus vaccines across key target groups in 118 nations (public/private)
worldwide including HI income and GAVI/developing world countries. A thorough review of latest disease background/epidemiology/resistance trends data is presented along with discussion
of latest understanding of vaccinology/R&D competitor landscape. The analysis contains an in-depth scenario-based commercial assessment of potential GBS vaccine profiles with discussion around target population rationale, potential uptake, pricing, cost-effectiveness and clinical development feasibility/issues. Insights from the 3rd ISSAD meeting, Rio de Janeiro, October 2023 and MRF meeting, London are now added.
THIS PRODUCT IS A SUMMARY PRESENTATION (~300 slides, .pdf) + 1 scenario-based interactive MS Excel Workbook(s)
Photo credit(s): iSTOCK images
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations).
Please review the TERMS and CONDITIONS of purchase.
